COVID-19 Pneumonia Clinical Trial
— TOLDOfficial title:
A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients
Verified date | April 2023 |
Source | UConn Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage from direct viral entry and proliferation. Dipyridamole has anti-platelet and anti-inflammatory effects. The drug was recently demonstrated to have anti-SARS-Cov-2 effect primarily in vitro. The concentration causing anti-viral effect in vitro is within that in the blood of humans taking this drug. As an oral tablet, it has the advantage of easy administration. Anti thrombotic, anti viral and anti inflammatory actions of this drug may be efficacious and safe in hospitalized subjects
Status | Terminated |
Enrollment | 41 |
Est. completion date | April 24, 2022 |
Est. primary completion date | March 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults =18 years of age. 2. COVID-19 positive by PCR and hospitalized for respiratory infection with a range of respiratory severity as follows. Moderate ? Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing ? Symptoms of moderate illness with COVID-19, which could include: o Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms; shortness of breath with exertion - Clinical signs suggestive of moderate illness with COVID-19, such as: o RR = 20, HR = 90, SaO2 =93% on room air or requires =2L oxygen by nasal cannula (NC) in order maintain SaO2 =93%, fever >38.3 Celsius - No clinical signs indicative of Severe or Critical Illness Severity Severe - Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing - Symptoms suggestive of severe systemic illness with COVID-19, which could include: o any symptom of Moderate Illness; shortness of breath at rest or respiratory distress - Clinical signs indicative of severe systemic illness with COVID-19, such as o RR = 30, HR = 125, requires > 2L oxygen by NC in order maintain SaO2 =93%, PaO2/FiO2 <300 - No criteria for Critical Severity Critical ? Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing - Evidence of critical illness, defined by at least 1 of the following: - Respiratory failure defined based on resource utilization requiring at least 1 of the following: ?, Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen =0.5), noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation) - Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring vasopressors) - Multiple organ dysfunction/failure 3. Able to give written informed consent in English to participate in the study by patient. - Exclusion Criteria: - Exclusion Criteria: 1. Inability to swallow or ingest oral medication in either tablet form or in suspension form. 2. Patient is known to be pregnant 3. Patients with a history of allergy or hypersensitivity to dipyridamole 4. Patient is unable to consent -intubated, on mechanical ventilation 5. Bleeding disorders (e.g. thrombocytopenia with platelet counts < 50,000) 6. Existing severe medical illnesses unrelated to Covid-19 infection such as end stage heart, kidney, liver disorders; or hepatic insufficiency defined as liver enzymes =5 times upper limit normal if baseline is normal or 5 times baseline if baseline is abnormal. Metastatic cancer as well as those with severe coronary artery disease, unstable angina, STEMI, NSTEMI, hypotension (systolic blood pressure <90mmHg), myocarditis, bradycardia with resting heart rate less than 60 bpm, atrioventricular block without pacemaker. Those with myasthenia gravis and those treated with cholinesterase inhibitors 7. Patient is enrolled in a clinical trial for another investigational drug designed to test for efficacy for SARS-CoV-2 |
Country | Name | City | State |
---|---|---|---|
United States | UConn Health | Farmington | Connecticut |
Lead Sponsor | Collaborator |
---|---|
UConn Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Survival | Survival Status Alive | 9 days | |
Other | Inflammatory Markers | Change in the markers CRP/Ferritin | 9 days | |
Other | Blood Markers | Change in Lymphocyte Count/ Fibrinogen/Cardiac Troponin | 9 days | |
Other | PT PTT | Coagulation System | 9 days | |
Other | Pulmonary Status | Change in SpO2/ imaging | 9 days | |
Other | Clinical Status | Change in fever, cough, sputum | 9 days | |
Primary | D-dimer | Percent Change from Baseline [Day Zero] to last study measure (Day 3, Day 6 or Day 9) | up to 9 days | |
Primary | Platelet Count | Percent Change from Baseline [Day Zero] to last study measure (Day 3, Day 6 or Day 9) | up to 9 days | |
Secondary | Viral Detection | Evaluate for a non-detection from nasopharyngeal swab and in stool | 9 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04901676 -
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
|
Phase 3 | |
Not yet recruiting |
NCT04534478 -
Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19
|
Phase 4 | |
Active, not recruiting |
NCT05002517 -
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
|
Phase 3 | |
Completed |
NCT05008393 -
Efficacy of PJS-539 for Adult Patients With COVID-19.
|
Phase 2 | |
Completed |
NCT04569877 -
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
|
Phase 2 | |
Not yet recruiting |
NCT05286255 -
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
|
Phase 1 | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Completed |
NCT06113432 -
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
|
N/A | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Recruiting |
NCT04615429 -
Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19
|
Phase 2 | |
Completed |
NCT05047653 -
RALE Versus CORADS/CT-Severity Score in COVID-19
|
||
Active, not recruiting |
NCT05047016 -
Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY
|
N/A | |
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
Completed |
NCT05504655 -
N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
|
||
Active, not recruiting |
NCT05035524 -
A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19
|
N/A | |
Completed |
NCT05065879 -
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
|
Phase 4 | |
Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
Withdrawn |
NCT04460105 -
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
|
Phase 1 | |
Suspended |
NCT04901689 -
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
|
Phase 3 |